Abstract
226 Phase I/IIa trial of volasertib combined with decitabine in patients with acute myeloid leukemia (AML) ineligible for intensive therapy Jorge E. Cortes, Nikolai Podoltsev, Sushmita Rajeswari, Zhenchao Guo, Tillmann Taube, Geoffrey L. Uy The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Internal Medicine, Hematology Section, Yale University School of Medicine, New Haven, Connecticut, USA; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA; Boehringer Ingelheim Pharma GmbH & Co. KG, Germany; Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
